ALFA Finder| Revenue growth | 42% YoY growth driven by JB Pharma acquisition and India business. |
|---|---|
| Margins | EBITDA margins maintained at 32.7% despite integration costs. |
| Demand visibility | Strong visibility in India chronic and Curatio portfolio demand. |
| Management confidence | High, particularly regarding synergy realization and India market outperformance. |
Growth
Consolidated revenue rose 42% YoY; organic base business grew 16% with robust chronic segment performance.
Outlook
Targeting 10-15% India growth and 7,500 total MR strength in FY27.
Risks
Middle East geopolitical tension impacting JB's international business and supply disruptions in Germany.
Earnings Call filed with NSE, NSE: TORNTPHARM. Summary written with AI assistance from the document.
Torrent Pharmaceuticals Ltd: key numbers
- Share price
- ₹4,761.00
- Market cap
- ₹1,81,093 Cr
- Revenue (annual)
- ₹13,980 Cr
- Net profit (annual)
- ₹2,163 Cr
- P/E (TTM)
- 85.3×Sector 43.8×
- Promoter holding
- 60.78%-7.53% QoQ
- FII holding
- 17.22%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Torrent Pharmaceuticals Ltd
All →Torrent Pharmaceuticals Debt & Borrowing: ₹100 Cr
Torrent Pharmaceuticals partially redeemed Rs.100 Crore of its unlisted secured NCDs on 09-11-2026, leaving Rs.300 Crore outstanding. This is a debt servicing event, not compliance paperwork.
- Value
- ₹100.0 Cr
Torrent Pharmaceuticals Legal & Regulatory
Torrent Pharma received a ₹3.12 Crore GST penalty order for pre-acquisition JB Chemicals periods. The company will appeal and expects no material impact.
- Value
- ₹3.12 Cr
Torrent Pharmaceuticals Other Announcement
Torrent Pharmaceuticals disclosed that its RTA, KFin Technologies, is moving its corporate office effective December 1, 2026. Investors should update their records with the new address.
Torrent Pharmaceuticals Earnings Call Transcript: Key Takeaways
Revenue grew 51% following the JB Chemicals merger, but underlying business shows integration headwinds.
- Call
- Guides 10% growth
Torrent Pharmaceuticals Debt & Borrowing
Torrent Pharmaceuticals filed its security cover certificate as on 30-Sep-26 for listed NCDs, showing 141% market-value cover. Secured debt covered by the certificate stands at Rs 11,578.42 Crore.
Torrent Pharmaceuticals Q2 FY27 Results: Net Profit ₹534 Cr, Down 9.6% YoY
Torrent Pharmaceuticals Ltd reported revenue from operations of ₹4,979 Cr (+50.8% YoY) and net profit of ₹534 Cr (-9.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹534 Cr · -9.6% YoY